p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies (Q37874926)

24 August 2017

1 reference

title

p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies (English)

1 reference

chronic lymphocytic leukemia

24 August 2017

0 references

1 reference

1 reference

R G Wickremasinghe

1

1 reference

PubMed ID

21566651

24 August 2017

A G Prentice

series ordinal

2

1 reference

PubMed ID

21566651

24 August 2017

A J Steele

series ordinal

3

1 reference

24 August 2017

13 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

25

1 reference

24 August 2017

9

1 reference

24 August 2017

1400-1407

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2011.103

24 August 2017

0 references

cites work

p53 in health and disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

21 January 2018

Modes of p53 regulation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

The p53 family and programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Outcomes of p53 activation--spoilt for choice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Transcription-independent pro-apoptotic functions of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Akt enhances Mdm2-mediated ubiquitination and degradation of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

The BCL-2 protein family: opposing activities that mediate cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

TIGAR, a p53-inducible regulator of glycolysis and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

The dark side of a tumor suppressor: anti-apoptotic p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Induction of apoptosis in HeLa cells by trans-activation-deficient p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Mitochondria and cell death: outer membrane permeabilization and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

PUMA couples the nuclear and cytoplasmic proapoptotic function of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Mitochondrially targeted p53 has tumor suppressor activities in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

p53 has a direct apoptogenic role at the mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Defining the p53 DNA-binding domain/Bcl-x(L)-binding interface using NMR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Dissecting p53-dependent apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Restoration of p53 expression in human cancer cell lines upregulates the expression of Notch1: implications for cancer cell fate determination after genotoxic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Notch signaling: the core pathway and its posttranslational regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Notch, a unifying target in T-cell acute lymphoblastic leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

TP53 mutation and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

21 January 2018

It's T-ALL about Notch

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

NOTCH1-induced T-cell leukemia in transgenic zebrafish.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to MDM2 inhibitor-mediated apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Restoration of p53 function leads to tumour regression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Therapeutic targeting of p53 by small molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Targeting the Notch1 and mTOR pathways in a mouse T-ALL model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Genetic determinants of p53-induced apoptosis and growth arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

inferred from DOI database lookup

7 January 2021

based on heuristic

A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

inferred from DOI database lookup

7 January 2021

based on heuristic

Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.103

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2011.103

1 reference

24 August 2017

1 reference

PubMed ID

21566651